Research Notes: A Deep Dive On SKIN
SKIN has bounced sharply after a post-earnings plunge
Beauty Health (SKIN) is a former high-flying de-SPAC whose 2023 performance has disappointed.
External factors and execution are mainly to blame. Demand for the underlying product remains reasonably healthy.
In that context, a 120% rally following a 66% post-earnings decline makes some sense — and might leave more upside ahead.